The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Real-world insights on redefining post-CD19 CAR T-cell surveillance with ctDNA
Snegha Ananth, MBBS, University of Nebraska Medical Center, Omaha, NE, shares real-world data supporting the use of circulating tumor DNA (ctDNA) as a sensitive tool for post-CD19 CAR T-cell surveillance in large B-cell lymphoma (LBCL). Early measurable residual disease (MRD) negativity, particularly after axicabtagene ciloleucel (axi-cel), strongly predicted durable remission and may enable MRD-adaptive strategies that reduce reliance on routine PET-CT imaging. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
